JACC. Heart failure · 2026
The MagMa Study: Quantum Magnetocardiography in Cardiomyopathy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Suwalski Phillip, Wilke Finn, Latinova Ekaterina, Paci Gabriele, Satilmis Gamze, Klingel Karin, Kelle Sebastian, Weiner January, Beule Dieter, Lüscher Thomas F, Landmesser Ulf, Heidecker Bettina
Аннотация
BACKGROUND: Rapid diagnostic screening is an unmet need in patients with suspected cardiomyopathy (CM). The authors recently demonstrated in a retrospective study that magnetocardiography (MCG) may be a suitable tool to detect CM.
OBJECTIVES: This study aims to prospectively evaluate the accuracy of MCG as a screening tool in patients with suspected CM.
METHODS: MCG uses a superconducting quantum interference device to detect the magnetic field of the heart. In another recent retrospective study by the same investigators, a T-beg-Tmax (MCG score) ≥0.051 identified patients with CM (dilated, hypertrophic, nondilated left ventricular, and restrictive CM) after exclusion of coronary artery disease. The authors assessed the diagnostic accuracy of MCG compared with advanced imaging and/or endomyocardial biopsy. The authors enrolled 110 adult patients with angina-like symptoms after exclusion of coronary artery disease from the emergency department, inpatient wards, and outpatient clinics. A total of 220 healthy individuals were incorporated into the study as control subjects by using 1:2 direct matching (age decade and sex) for a total of 330 participants.
RESULTS: MCG detected CM with 94.74% sensitivity (95% CI: 85%-99%), 98.54% specificity (95% CI: 96%-100%), 93.1% negative predictive value (95% CI: 84%-98%), and 94.34% positive predictive value (95% CI: 84%-98%). In 3 patients, cardiac magnetic resonance failed to detect CM, whereas MCG showed pathologic results consistent with results of endomyocardial biopsy. Results were highly reproducible (statistical uncertainty: 2.5%, T-beg-Tmax [interval and electrical vector from the beginning of a T-wave to its peak (MCG score)] ±0.004).
CONCLUSIONS: MCG offers a noninvasive, reproducible methodology for rapid and accurate detection of CM after exclusion of ischemic heart disease. Our data indicate that MCG may be an efficient tool for allocation of advanced imaging to those patients with a high likelihood of disease. (Magnetocardiography as a Diagnostic Screening Tool for Myocarditis and Other Types of Cardiomyopathy [MagMa]; NCT06689098).
OBJECTIVES: This study aims to prospectively evaluate the accuracy of MCG as a screening tool in patients with suspected CM.
METHODS: MCG uses a superconducting quantum interference device to detect the magnetic field of the heart. In another recent retrospective study by the same investigators, a T-beg-Tmax (MCG score) ≥0.051 identified patients with CM (dilated, hypertrophic, nondilated left ventricular, and restrictive CM) after exclusion of coronary artery disease. The authors assessed the diagnostic accuracy of MCG compared with advanced imaging and/or endomyocardial biopsy. The authors enrolled 110 adult patients with angina-like symptoms after exclusion of coronary artery disease from the emergency department, inpatient wards, and outpatient clinics. A total of 220 healthy individuals were incorporated into the study as control subjects by using 1:2 direct matching (age decade and sex) for a total of 330 participants.
RESULTS: MCG detected CM with 94.74% sensitivity (95% CI: 85%-99%), 98.54% specificity (95% CI: 96%-100%), 93.1% negative predictive value (95% CI: 84%-98%), and 94.34% positive predictive value (95% CI: 84%-98%). In 3 patients, cardiac magnetic resonance failed to detect CM, whereas MCG showed pathologic results consistent with results of endomyocardial biopsy. Results were highly reproducible (statistical uncertainty: 2.5%, T-beg-Tmax [interval and electrical vector from the beginning of a T-wave to its peak (MCG score)] ±0.004).
CONCLUSIONS: MCG offers a noninvasive, reproducible methodology for rapid and accurate detection of CM after exclusion of ischemic heart disease. Our data indicate that MCG may be an efficient tool for allocation of advanced imaging to those patients with a high likelihood of disease. (Magnetocardiography as a Diagnostic Screening Tool for Myocarditis and Other Types of Cardiomyopathy [MagMa]; NCT06689098).